Monograph Capital Partners — 2025 Investments

1 investments dated 2025 · listed companies and verified rows first · show all

Nocion Therapeuticsnociontx.comin 𝕏Dec 2025

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.

BiotechHealthtechMedical DevicesWatertown, US

MATTHEW FRANKEL(Executive Officer)PETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MEREDITH FISHER(Director)MICHAEL LIPP(Executive Officer)

Board seatFreddie Dear· per SEC Form D

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.